论文部分内容阅读
目的探讨培美曲塞联合铂类治疗晚期复发性非小细胞肺癌(NSCLC)的疗效以及不良反应。方法经病理学或细胞学确诊的复发性晚期NSCLC患者12例,培美曲塞500 mg/m2第1天静脉滴注,卡铂(AUC=5)第1天静脉滴注或顺铂75 mg/m2每4周重复,至少应用2个周期以上评价疗效及不良反应。结果 12例患者,完全缓解1例,部分缓解2例,稳定5例,进展4例。缓解率25%,疾病控制率66.7%。不良反应主要为轻中度的胃肠道反应和骨髓抑制。结论培美曲塞联合铂类治疗晚期复发性非小细胞肺癌疗效确切,不良反应可耐受。
Objective To investigate the efficacy and adverse reactions of pemetrexed combined with platinum in the treatment of advanced recurrent non-small cell lung cancer (NSCLC). Methods Twelve patients with recurrent advanced NSCLC diagnosed by pathology or cytology were enrolled in this study. Pemetrexed 500 mg / m2 was given intravenously on the first day, carboplatin (AUC = 5) intravenously on the first day or cisplatin 75 mg / m2 repeated every 4 weeks, at least 2 cycles to evaluate efficacy and adverse reactions. Results In 12 patients, complete remission in 1 case, partial remission in 2 cases, stable in 5 cases and progression in 4 cases. The remission rate was 25% and the disease control rate was 66.7%. Adverse reactions are mainly mild to moderate gastrointestinal reactions and bone marrow suppression. Conclusion Pemetrexed combined with platinum treatment of advanced recurrent non-small cell lung cancer is effective and can tolerate adverse reactions.